Internet use among docs increases

Share this article:
The number of physicians interacting with drug and device companies online has grown 23% since 2004 to comprise 87% of all US physicians, according to Manhattan Research. 
         
The research firm's ePharma Physician study found that physicians would like to use more online conferences and professional online videos for pharmaceutical, biotech and medical device product information. Physicians also show significant interest in reading medical journals online.

The study found many companies trying to integrate their sales force, marketing, and customer service functions to create a more seamless customer experience for physicians. For some practitioners, physician service portals can act as the hub of a physician's relationship with a brand. Leading portals include Shire Connect, WyethHCP.com, MerckServices and Pfizer for Professionals.       

Physician expectations of online customer service continues to increase, the study found, and as a result, companies are including relevant and useful content and tools on these portals, including: product information, links to patient education, electronic sampling, and online customer service reps. Formulary information, in particular, is a feature that physicians increasingly want to see from manufacturers, according to the study.

Physicians also visit the product websites themselves when researching treatment information. Shire's ADHD treatment Vyvanse boasts the most popular product site among pediatricians, and Merck's Januvia took the top spot among primary care physicians, according to the study.


Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...